Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine

Vaccine

Volumn 29, Issue 32, 2011, Pages 5221-5231

  Velasquez, Lissette S ^a   Shira, Samantha ^a   Berta, Alice N ^a   Kilbourne, Jacquelyn ^a   Medi, Babu M ^b,f   Tizard, Ian ^c   Ni, Yawei ^b,g   Arntzen, Charles J ^a,d   Herbst Kralovetz, Melissa M ^a,e  

^a ARIZONA STATE UNIVERSITY   (United States)

^b DelSite Biotechnologies Inc   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g NANO ADM Advanced Development and Manufacturing Center   (United States)

Author keywords

Intranasal delivery; Mucoadhesive; Norovirus vaccine; Spray dry powder formulation; TLR agonist; Virus like particles (VLP)

Indexed keywords

ALOE VERA EXTRACT; GELSITE; GELVAC; POLYGALACTURONIC ACID; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; GEL; GELATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; MUCOCILIARY CLEARANCE; NONHUMAN; NOROVIRUS; NOSE MUCUS; PRIORITY JOURNAL; RAT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CALICIVIRIDAE INFECTIONS; CELL LINE; FEMALE; GUINEA PIGS; HUMANS; MICE; MICROSCOPY, ELECTRON; MUCOUS MEMBRANE; NOROVIRUS; POLYSACCHARIDES; POWDERS; RATS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 79960323464     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.027     Document Type: Article

References (59)

1. Patel M.M., Hall A.J., Vinje J., Parashar U.D. Noroviruses a comprehensive review. J Clin Virol 2009, 44(January (1)):1-8.
2. Patel M.M., Widdowson M.A., Glass R.I., Akazawa K., Vinje J., Parashar U.D. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008, 14(August (8)):1224-1231.
3. Glass R.I., Parashar U.D., Estes M.K. Norovirus gastroenteritis. N Engl J Med 2009, 361(October (18)):1776-1785.
4. Velasquez L.S., Hjelm B.E., Arntzen C.J., Herbst-Kralovetz M.M. An intranasally delivered Tlr7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol 2010, 17(December (12)):1850-1858.
5. Guerrero R.A., Ball J.M., Krater S.S., Pacheco S.E., Clements J.D., Estes M.K. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 2001, 75(October (20)):9713-9722.
6. Mason H.S., Ball J.M., Shi J.J., Jiang X., Estes M.K., Arntzen C.J. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A 1996, 93(May (11)):5335-5340.
7. Ball J.M., Hardy M.E., Atmar R.L., Conner M.E., Estes M.K. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998, 72(February (2)):1345-1353.
8. Estes M.K., Ball J.M., Guerrero R.A., Opekun A.R., Gilger M.A., Pacheco S.S., et al. Norwalk virus vaccines: challenges and progress. J Infect Dis 2000, 81(May (Suppl 2)):S367-S373.
9. Herbst-Kralovetz M., Mason H.S., Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines 2010, 9(March (3)):299-307.
10. Ball J.M., Graham D.Y., Opekun A.R., Gilger M.A., Guerrero R.A., Estes M.K. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999, 117(July (1)):40-48.
11. Tacket C.O., Mason H.S., Losonsky G., Estes M.K., Levine M.M., Arntzen C.J. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000, 182(July (1)):302-305.
12. El-Kamary S.S., Pasetti M.F., Mendelman P.M., Frey S.E., Bernstein D.I., Treanor J.J., et al. Adjuvanted intranasal norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010, 202(December (11)):1649-1658.
13. Green K.Y., Lew J.F., Jiang X., Kapikian A.Z., Estes M.K. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol 1993, 31(August (8)):2185-2191.
14. Reeck A., Kavanagh O., Estes M.K., Opekun A.R., Gilger M.A., Graham D.Y., et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010, 202(October (8)):1212-1218.
15. van Ginkel F.W., Nguyen H.H., McGhee J.R. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis 2000, 6(March-April (2)):123-132.
16. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(April (4 Suppl)):S45-53.
17. Holmgren J., Harandi A.M., Czerkinsky C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev Vaccines 2003, 2(April (2)):205-217.
18. Yuki Y., Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines 2009, 8(August (8)):1083-1097.
19. Chadwick S., Kriegel C., Amiji M. Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther 2009, 9(April (4)):427-440.
20. Kuolee R., Chen W. M cell-targeted delivery of vaccines and therapeutics. Expert Opin Drug Deliv 2008, 5(June (6)):693-702.
21. Graham B.S., Kines R.C., Corbett K.S., Nicewonger J., Johnson T.R., Chen M., et al. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plas- 765 mids improves the potency of DNA vaccination. Mucosal Immunol 2010, 3(5):475-486.
22. Inskeep T.K., Stahl C., Odle J., Oakes J., Hudson L., Bost K.L., et al. Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B using a piglet model. Clin Vaccine Immunol. 2010, 17(8):1163-1169.
23. Fraillery D., Zosso N., Nardelli-Haefliger D. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine 2009, 27(April (17)):2326-2334.
24. Noda K., Kodama S., Umemoto S., Abe N., Hirano T., Suzuki M. Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx. Vaccine. 2010, 28(July (31)):5068-5074.
25. Hefferon K.L. The mucosal immune response to plant-derived vaccines. Pharm Res 2010, 27(10):2040-2042.
26. Lanza S.R., Menin A., Ertl H.C., Bafica A., Pinto A.R. Simian recombinant adenovirus delivered by the mucosal route modulates gamma-delta T cells from murine genital tract. Vaccine 2010, 28(June (29)):4600-4608.
27. Huang J., Garmise R.J., Crowder T.M., Mar K., Hwang C.R., Hickey A.J., et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 2004, 23(December (6)):794-801.
28. Garmise R.J., Staats H.F., Hickey A.J. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech 2007, 8(4):E81.
29. Turker S., Onur E., Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004, 26(June (3)):137-142.
30. Jiang L., Gao L., Wang X., Tang L., Ma J. The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm 2010, 36(March (3)):323-336.
31. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987, 7(July (4)):265-276.
32. Hickey A.J., Garmise R.J. Dry powder nasal vaccines as an alternative to needle-based delivery. Crit Rev Ther Drug Carrier Syst 2009, 26(1):1-27.
33. Treanor J.J., Kotloff K., Betts R.F., Belshe R., Newman F., Iacuzio D., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18(December (9-10)):899-906.
34. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999, 282(July (2)):137-144.
35. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338(May (20)):1405-1412.
36. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 2001, 51(September (1-3)):21-42.
37. Buonaguro L., Visciano M.L., Tornesello M.L., Tagliamonte M., Biryahwaho B., Buonaguro F.M. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005, 79(June 11):7059-7067.
38. Balmelli C., Roden R., Potts A., Schiller J., De Grandi P., Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998, 72(October (10)):8220-8229.
39. Nardelli-Haefliger D., Roden R., Balmelli C., Potts A., Schiller J., De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol 1999, 73(November (11)):9609-9613.
40. Canessa C., Vierucci S., Azzari C., Vierucci A. The immunity of upper airways. Int J Immunopathol Pharmacol 2010, 23(January-March (1 Suppl)):8-12.
41. Garg N.K., Mangal S., Khambete H., Sharma P.K., Tyagi R.K. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 2010, 4(June (2)):114-128.
42. Patil S.B., Sawant K.K. Mucoadhesive microspheres: a promising tool in drug delivery. Curr Drug Deliv 2008, 5(October (4)):312-318.
43. Pawar D., Goyal A.K., Mangal S., Mishra N., Vaidya B., Tiwari S., et al. Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 2010, 12(June (2)):130-137.
44. Jiang L., Gao L., Wang X., Tang L., Ma J. The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm 2010, 36(March (3)):323-336.
45. Ni YaY, KM. Inventor in situ gel formation of pectin. USA Patent 6,777,000 B2; 2004.
46. Huang Z., Elkin G., Maloney B.J., Beuhner N., Arntzen C.J., Thanavala Y., et al. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 2005, 23(March (15)):1851-1858.
47. Santi L., Batchelor L., Huang Z., Hjelm B., Kilbourne J., Arntzen C.J., et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008, 26(March (15)):1846-1854.
48. Lorin M.I., Gaerlan P.F., Mandel I.D. Quantitative composition of nasal secretions in normal subjects. J Lab Clin Med 1972, 80(August (2)):275-281.
49. Saluja V., Amorij J.P., Kapteyn J.C., de Boer A.H., Frijlink H.W., Hinrichs W.L. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release 2010, 144(June (2)):127-133.
50. Rutland J., Cole P.J. Nasal mucociliary clearance and ciliary beat frequency in cystic fibrosis compared with sinusitis and bronchiectasis. Thorax 1981, 36(September (9)):654-658.
51. Pandey R.S., Babbar A.K., Kaul A., Mishra A.K., Dixit V.K. Evaluation of ISCOM matrices clearance from rabbit nasal cavity by gamma scintigraphy. Int J Pharm 2010, 398(October (1-2)):231-236.
52. Ni YaY, KM. Inventor delivery of physiological agents with in-situ gels comprising anionic polysaccharides. USA Patent 7,494,669; 2009.
53. Alpar H.O., Somavarapu S., Atuah K.N., Bramwell V.W. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005, 57(January (3)):411-430.
54. Bernstein D.I., Harrison C.J., Tomai M.A., Miller R.L. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis 2001, 183(March (6)):844-849.
55. Bernstein D.I., Harrison C.J., Tepe E.R., Shahwan A., Miller R.L. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs. Vaccine 1995, 13(January (1)):72-76.
56. Wimer-Mackin S., Hinchcliffe M., Petrie C.R., Warwood S.J., Tino W.T., Williams M.S., et al. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 2006, 24(May (18)):3953-3963.
57. Tafaghodi M., Rastegar S. Preparation and in vivo study of dry powder microspheres for nasal immunization. J Drug Target 2010, 18(April (3)):235-242.
58. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G.C., Vedvick T.S., et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009, 27(May (23)):3063-3071.
59. Ma Y., Poisson L., Sanchez-Schmitz G., Pawar S., Qu C., Randolph G.J., et al. Assessing the immunopotency of toll-like receptor agonists in an in vitro tissue-engineered immunological model. Immunology 2010, 130(July (3)):374-387.